Autolus Therapeutics plc
AUTL Nasdaq
SEC CIK 1730463
Follow Autolus Therapeutics
Weekly email: filings, results
Revenue, last quarter
$41.2M
+94.6% vs same quarter last year
Net income
−$55.1M
+30.4% vs same quarter last year
EPS, diluted
−$0.21
+30% vs same quarter last year
Operating cash flow
−$18.5M
+72.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $75.4M | −$287.5M |
| FY24 | $10.1M | −$220.7M |
| FY23 | $1.7M | −$208.4M |
| FY22 | - | −$148.8M |
| FY21 | - | −$142.1M |
| FY20 | - | −$142.1M |
| FY19 | $2.9M | −$123.8M |
| FY18 | $1.4M | −$44.8M |
| FY17 | $1.7M | −$19.7M |
| FY16 | $1.2M | −$12.6M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | −27.8% | −358.9% | −381.4% |
| FY24 | −12.5% | −2385.6% | −2180.5% |
| FY23 | 100% | −10583.1% | −12272.3% |
| FY22 | - | - | - |
| FY21 | - | - | - |
| FY20 | - | - | - |
| FY19 | - | −5022.8% | −4258.9% |
| FY18 | - | −4089.1% | −3180.6% |
| FY17 | - | −1383.2% | −1165.2% |
| FY16 | - | - | −1035.5% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$302.6M |
| FY24 | −$228.3M |
| FY23 | −$156.6M |
| FY22 | −$123.1M |
| FY21 | −$126.7M |
| FY20 | −$132.4M |
| FY19 | −$119.8M |
| FY18 | −$40.7M |
| FY17 | −$19.2M |
| FY16 | −$11.7M |
- Autolus Therapeutics
- Healthcare median
Show the numbers
| Year | Autolus Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −381.4% | −30.6% |
| FY24 | −2180.5% | −47% |
| FY23 | −12272.3% | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.9% |
| FY20 | - | −62.2% |
| FY19 | −4258.9% | −46.3% |
| FY18 | −3180.6% | −49.6% |
| FY17 | −1165.2% | −45.9% |
| FY16 | −1035.5% | −36% |